CEO Must leave. Now not tomorrow.Silly comment from the CEO; ''
All future clinical research activities in oncology and NASH will be made through partnership deals.''. As usual, Paul Lvesque, is sending the same ineffective message to the market . From where did he get this bright idea of finding partners that can execute TH oncology and Nash future developments. He tried for years to get some interests from chineese and other bio-pharma players in regard to the Nash program, in vain!
He continues to provide his misleading information but the market knows all the facts. The only reality we can derive from this message is that the ovarian cancer testing didn't work well and they have to stop everything. They want to focus on commercial through legacy drugs (Trogarzon and Egrifta) and nothing else, which makes the company a bit more profitable but not that much if those legacy drugs stagnate over time.
Paul lvesque should resign and let someone else, anyone, lead the company. I say anyone because anyone can do better than him!